Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

LENZ Therapeutics (LENZ) Shares Outstanding (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Shares Outstanding for 4 consecutive years, with $31.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 13.9% to $31.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.3 million through Dec 2025, up 13.9% year-over-year, with the annual reading at $31.3 million for FY2025, 13.9% up from the prior year.
  • Shares Outstanding for Q4 2025 was $31.3 million at LENZ Therapeutics, up from $28.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $58.2 million in Q2 2022, with the low at $1.9 million in Q4 2022.
  • Average Shares Outstanding over 4 years is $34.4 million, with a median of $28.5 million recorded in 2025.
  • Peak annual rise in Shares Outstanding hit 27887.23% in 2023, while the deepest fall reached 96.64% in 2023.
  • Over 4 years, Shares Outstanding stood at $1.9 million in 2022, then soared by 2877.52% to $58.0 million in 2023, then tumbled by 52.53% to $27.5 million in 2024, then grew by 13.9% to $31.3 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $31.3 million, $28.6 million, and $28.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.